Zeleciment Biosimilar – Anti-Transferrin receptor protein 1 mAb – Research Grade

Description of Zeleciment Biosimilar - Anti-Transferrin receptor protein 1 mAb - Research Grade

Introduction:

Zeleciment Biosimilar is a novel therapeutic antibody that targets the Transferrin receptor protein 1 (TfR1), a key protein involved in iron metabolism and cellular proliferation. This biosimilar has been developed as a potential treatment for various diseases, including cancer, anemia, and neurodegenerative disorders. In this article, we will discuss the structure, activity, and potential applications of Zeleciment Biosimilar in detail.

Structure of Zeleciment Biosimilar:

Zeleciment Biosimilar is a monoclonal antibody (mAb) that specifically binds to TfR1. It is a recombinant protein, produced by cloning the gene encoding for the mAb into a suitable expression system, such as Chinese hamster ovary (CHO) cells. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains contain a constant region (Fc) and a variable region (Fab), while the light chains contain only a variable region. The Fab region is responsible for binding to TfR1, while the Fc region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Zeleciment Biosimilar:

Zeleciment Biosimilar exerts its therapeutic effects by targeting TfR1, which is overexpressed in various cancer cells and is essential for their survival and proliferation. Upon binding to TfR1, Zeleciment Biosimilar blocks the uptake of transferrin-bound iron, leading to iron depletion and subsequent cell death. This mechanism of action makes Zeleciment Biosimilar a promising candidate for the treatment of cancer, as well as other diseases characterized by abnormal iron metabolism, such as anemia and neurodegenerative disorders.

In addition to its direct effects on TfR1, Zeleciment Biosimilar also has immune-modulating properties. It can activate the immune system by binding to Fc receptors on immune cells, such as natural killer (NK) cells and macrophages, leading to the destruction of cancer cells through ADCC and CDC. This dual mechanism of action makes Zeleciment Biosimilar a potent and versatile therapeutic agent.

Applications of Zeleciment Biosimilar:

Zeleciment Biosimilar is currently being evaluated in preclinical and clinical studies for the treatment of various types of cancer, including breast, lung, and colorectal cancer. It has also shown promising results in the treatment of anemia, particularly in patients with chronic kidney disease and myelodysplastic syndromes. In addition, Zeleciment Biosimilar has potential applications in the treatment of neurodegenerative disorders, such as Alzheimer’s disease, as it has been shown to reduce iron accumulation and improve cognitive function in animal models.

Conclusion:

In summary, Zeleciment Biosimilar is a novel therapeutic antibody that targets TfR1 and has potential applications in the treatment of cancer, anemia, and neurodegenerative disorders. Its unique mechanism of action, as well as its immune-modulating properties, make it a promising candidate for various diseases. Further studies are needed to fully understand the therapeutic potential of Zeleciment Biosimilar and to bring this promising biosimilar to the market.